Guardant Health, Inc. $GH Holdings Lifted by Geode Capital Management LLC

Geode Capital Management LLC raised its position in Guardant Health, Inc. (NASDAQ:GH) by 0.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 2,920,714 shares of the company’s stock after acquiring an additional 13,088 shares during the quarter. Geode Capital Management LLC’s holdings in Guardant Health were worth $152,014,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in GH. Envestnet Asset Management Inc. grew its holdings in Guardant Health by 136.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 27,497 shares of the company’s stock worth $1,171,000 after buying an additional 15,877 shares in the last quarter. New York State Common Retirement Fund boosted its position in Guardant Health by 184.1% during the 1st quarter. New York State Common Retirement Fund now owns 106,884 shares of the company’s stock worth $4,553,000 after acquiring an additional 69,257 shares during the period. CWM LLC grew its stake in shares of Guardant Health by 180.3% in the first quarter. CWM LLC now owns 2,296 shares of the company’s stock worth $98,000 after purchasing an additional 1,477 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Guardant Health by 1,410.0% in the first quarter. Victory Capital Management Inc. now owns 220,124 shares of the company’s stock worth $9,377,000 after purchasing an additional 205,546 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Guardant Health during the first quarter valued at $6,652,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Down 0.9%

Shares of NASDAQ GH opened at $95.57 on Wednesday. Guardant Health, Inc. has a twelve month low of $28.45 and a twelve month high of $101.57. The firm has a 50-day moving average of $72.20 and a two-hundred day moving average of $57.49. The company has a market capitalization of $12.05 billion, a price-to-earnings ratio of -29.77 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same quarter last year, the firm posted ($0.88) earnings per share. The business’s revenue was up 38.5% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. As a group, research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the transaction, the director directly owned 851 shares in the company, valued at $46,090.16. The trade was a 71.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total value of $17,835,000.00. Following the sale, the chief executive officer directly owned 2,123,499 shares in the company, valued at $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 313,045 shares of company stock valued at $18,984,897. Corporate insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on GH shares. Cowen restated a “buy” rating on shares of Guardant Health in a research note on Thursday, October 30th. BTIG Research raised their target price on shares of Guardant Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Mizuho set a $100.00 price target on shares of Guardant Health in a research report on Thursday, October 30th. Evercore ISI increased their price objective on shares of Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, William Blair reiterated an “outperform” rating on shares of Guardant Health in a research note on Thursday, September 25th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $77.14.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.